res_code stringlengths 6 13 | treatment_phase stringclasses 432
values | authority_method stringclasses 3
values | treatment_of_code float64 4.08k 16.5k ⌀ | restriction_number float64 4.08k 16.5k ⌀ | li_html_text stringlengths 82 10.6k ⌀ | schedule_html_text stringlengths 41 12.3k | note_indicator stringclasses 2
values | caution_indicator stringclasses 2
values | complex_authority_rqrd_ind stringclasses 2
values | assessment_type_code stringclasses 2
values | criteria_relationship stringclasses 1
value | variation_rule_applied stringclasses 2
values | first_listing_date stringdate 1991-08-01 00:00:00 2025-05-01 00:00:00 | schedule_code int64 3.67k 3.67k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10760_10766_R | null | RESTRICTED | 10,766 | 10,760 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>The treatment must be for short term therapy of acute severe pain; AND</p> <p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or</p> <p>Patient must be una... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>The treatment must be for short term therapy of acute severe pain; AND</p> <p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or</p> <p>Patient must be una... | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10761_10772_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | RESTRICTED | 10,772 | 10,761 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10763_10777_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | RESTRICTED | 10,777 | 10,763 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10764_10764_R | Continuing PBS treatment after 1 June 2020 | RESTRICTED | 10,764 | 10,764 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">Palliative care nur... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">Palliative care nur... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10767_10768_R | null | RESTRICTED | 10,768 | 10,767 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or</p> <p>Patient must be unable to use non-opioid analgesics due to contraindications or intolerance.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or</p> <p>Patient must be unable to use non-opioid analgesics due to contraindications or intolerance.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10769_10765_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | RESTRICTED | 10,765 | 10,769 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10773_10771_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | RESTRICTED | 10,771 | 10,773 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10774_10891_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | RESTRICTED | 10,891 | 10,774 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cancer pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have cancer pain; AND</p> <p>Patient must have had or would have inadequate pain management w... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cancer pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have cancer pain; AND</p> <p>Patient must have had or would have inadequate pain management w... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10775_10775_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | RESTRICTED | 10,775 | 10,775 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cancer pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have cancer pain; AND</p> <p>Patient must have had or would have inadequate pain management w... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cancer pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have cancer pain; AND</p> <p>Patient must have had or would have inadequate pain management w... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10776_10770_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | RESTRICTED | 10,770 | 10,776 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10793_10830_R | null | STREAMLINED | 10,830 | 10,793 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10805_10807_R | Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply | AUTHORITY_REQUIRED | 10,807 | 10,805 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug under the continuing treatment, Whol... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug under the continuing treatment, Whol... | N | N | Y | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10814_10814_R | Continuing PBS treatment after 1 June 2020 | AUTHORITY_REQUIRED | 10,814 | 10,814 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">P... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10815_10859_R | null | RESTRICTED | 10,859 | 10,815 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics; or</p> <p>Patient must be unable to use non-opioid and other opioid analgesics due to cont... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics; or</p> <p>Patient must be unable to use non-opioid and other opioid analgesics due to cont... | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10816_10762_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | RESTRICTED | 10,762 | 10,816 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10835_10756_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | AUTHORITY_REQUIRED | 10,756 | 10,835 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Pat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Pat... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10837_10837_R | Continuing PBS treatment after 1 June 2020 | RESTRICTED | 10,837 | 10,837 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cancer pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">Palliative care nur... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cancer pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">Palliative care nur... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10851_10802_R | Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 10,802 | 10,851 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10856_10742_R | Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 10,742 | 10,856 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10858_10858_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | AUTHORITY_REQUIRED | 10,858 | 10,858 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Pat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Pat... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10864_10863_R | null | STREAMLINED | 10,863 | 10,864 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10874_8877_R | Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3, Whole body or Face, hand, foot (re-commencement of treatment after a break in biologic... | AUTHORITY_REQUIRED | 8,877 | 10,874 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | N | N | Y | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10877_10836_R | null | AUTHORITY_REQUIRED | 10,836 | 10,877 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Patient must have cancer pain; or</p> <p>Patient must have had or would have inadequate pain management with maximum toler... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe disabling pain</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Patient must have cancer pain; or</p> <p>Patient must have had or would have inadequate pain management with maximum toler... | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10890_10890_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | RESTRICTED | 10,890 | 10,890 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have cancer pain; or</p> <p>The treatment must be for post-operative pain following a major o... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>Patient must have cancer pain; or</p> <p>The treatment must be for post-operative pain following a major o... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10903_10910_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | RESTRICTED | 10,910 | 10,903 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have cancer pain; or</p> <p>The treatment must be for post-operative pain following a major o... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>Patient must have cancer pain; or</p> <p>The treatment must be for post-operative pain following a major o... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10905_10853_R | Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 10,853 | 10,905 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10906_10743_R | Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 10,743 | 10,906 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10907_10901_R | Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 10,901 | 10,907 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10909_10860_R | null | RESTRICTED | 10,860 | 10,909 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>The treatment must be for post-operative pain following a major operative procedure; AND</p> <p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or</p> <p>P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>The treatment must be for post-operative pain following a major operative procedure; AND</p> <p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or</p> <p>P... | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10909_N | null | null | null | null | null | <p>OxyContin modified release tablets are intended to be crush-deterrent and to reduce the rapid release of oxycodone upon accidental or intentional misuse.</p> | Y | N | N | null | null | N | 2014-08-01 | 3,671 |
10917_10917_R | Continuing treatment of hepatocellular carcinoma - 3 weekly treatment regimen | STREAMLINED | 10,917 | 10,917 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Continuing treatment of hepatocellular carcinoma - 3 weekly treatment regimen</p><br/><p>Patient must be undergoing combination treatment w... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Continuing treatment of hepatocellular carcinoma - 3 weekly treatment regimen</p><br/><p>Patient must be undergoing combination treatment w... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10918_9209_R | Continuing treatment | STREAMLINED | 9,209 | 10,918 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Dermatofibrosarcoma protuberans</p><br/><p>Continuing treatment</p><br/><p>The condition must be unresectable; or</p> <p>The condition must be locally recurrent; or</p> <p>The condition must be metastatic; AND</p> <p>Patient must have previously re... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Dermatofibrosarcoma protuberans</p><br/><p>Continuing treatment</p><br/><p>The condition must be unresectable; or</p> <p>The condition must be locally recurrent; or</p> <p>The condition must be metastatic; AND</p> <p>Patient must have previously re... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10919_6137_R | Initial treatment for up to 6 months | STREAMLINED | 6,137 | 10,919 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gast... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gast... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10923_6182_R | Continuing treatment | STREAMLINED | 6,182 | 10,923 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist a... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist a... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10934_10968_R | Continuing or change of treatment | AUTHORITY_REQUIRED | 10,968 | 10,934 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Continuing or change of treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; or</p> <p>Patient must have previously received PBS-subsidised treatment with armod... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Continuing or change of treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; or</p> <p>Patient must have previously received PBS-subsidised treatment with armod... | N | N | Y | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10936_10935_R | Initial 2 - treatment of narcolepsy with cataplexy | AUTHORITY_REQUIRED | 10,935 | 10,936 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Initial 2 - treatment of narcolepsy with cataplexy</p><br/><p>Must be treated by a qualified sleep medicine practitioner or neurologist; AND</p> <p>The treatment must be for use when therapy with dexamfetamine sulfate poses an... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Initial 2 - treatment of narcolepsy with cataplexy</p><br/><p>Must be treated by a qualified sleep medicine practitioner or neurologist; AND</p> <p>The treatment must be for use when therapy with dexamfetamine sulfate poses an... | N | N | Y | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10939_10939_R | Initial treatment | STREAMLINED | 10,939 | 10,939 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Initial treatment</p><br/><p>Patient must be undergoing combination treatment with bevacizumab and atezolizumab until disease progression, ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Initial treatment</p><br/><p>Patient must be undergoing combination treatment with bevacizumab and atezolizumab until disease progression, ... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10940_9243_R | Continuing treatment | STREAMLINED | 9,243 | 10,940 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Myelodysplastic or myeloproliferative disorder</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The condition must be PDGFRB fusion gene-positive... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Myelodysplastic or myeloproliferative disorder</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The condition must be PDGFRB fusion gene-positive... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10941_6148_R | null | STREAMLINED | 6,148 | 10,941 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe diarrhoea of greater than 2 weeks duration</p><br/><p>Patient must be aged less than 4 months.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe diarrhoea of greater than 2 weeks duration</p><br/><p>Patient must be aged less than 4 months.</p> <p>No increase in the maximum quantity or number of units may be authorised.</p> <p>No increase in the maximum number of repeats may be author... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10949_10970_R | Initial 1 - treatment of narcolepsy without cataplexy | AUTHORITY_REQUIRED | 10,970 | 10,949 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Initial 1 - treatment of narcolepsy without cataplexy</p><br/><p>Must be treated by a qualified sleep medicine practitioner or neurologist; AND</p> <p>The treatment must be for use when therapy with dexamfetamine sulfate poses... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Initial 1 - treatment of narcolepsy without cataplexy</p><br/><p>Must be treated by a qualified sleep medicine practitioner or neurologist; AND</p> <p>The treatment must be for use when therapy with dexamfetamine sulfate poses... | N | N | Y | FULL | ALL | N | 2020-11-01 | 3,671 |
10950_10988_R | Continuing treatment | STREAMLINED | 10,988 | 10,950 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have received PBS-subsidised treatment with this drug for this PBS indication; AND</p> <p>Patient must have demonstrated a response ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have received PBS-subsidised treatment with this drug for this PBS indication; AND</p> <p>Patient must have demonstrated a response ... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10951_10985_R | Initial treatment | STREAMLINED | 10,985 | 10,951 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Initial treatment</p><br/><p>Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment wit... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Initial treatment</p><br/><p>Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment wit... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10961_6174_R | Initial treatment | STREAMLINED | 6,174 | 10,961 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy and intolerance to soy protein</p><br/><p>Initial treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepato... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy and intolerance to soy protein</p><br/><p>Initial treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepato... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10969_10967_R | Continuing or change of treatment | AUTHORITY_REQUIRED | 10,967 | 10,969 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Continuing or change of treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; or</p> <p>Patient must have previously received PBS-subsidised treatment with modaf... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Narcolepsy</p><br/><p>Continuing or change of treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; or</p> <p>Patient must have previously received PBS-subsidised treatment with modaf... | N | N | Y | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10971_10971_R | Initial treatment | STREAMLINED | 10,971 | 10,971 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Initial treatment</p><br/><p>Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment wit... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Initial treatment</p><br/><p>Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment wit... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10972_10972_R | Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen | STREAMLINED | 10,972 | 10,972 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen</p><br/><p>Patient must have previously received PBS-su... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen</p><br/><p>Patient must have previously received PBS-su... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10982_6204_R | null | STREAMLINED | 6,204 | 10,982 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy and intolerance to soy protein</p><br/><p>Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist; AND</p> <p>The condit... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy and intolerance to soy protein</p><br/><p>Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist; AND</p> <p>The condit... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10986_6193_R | Continuing treatment | STREAMLINED | 6,193 | 10,986 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy and intolerance to soy protein</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hep... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy and intolerance to soy protein</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hep... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10989_10989_R | Continuing treatment | STREAMLINED | 10,989 | 10,989 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have received PBS-subsidised treatment with this drug for this PBS indication; AND</p> <p>Patient must have demonstrated a response ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have received PBS-subsidised treatment with this drug for this PBS indication; AND</p> <p>Patient must have demonstrated a response ... | N | N | N | IMMEDIATE | ALL | N | 2020-11-01 | 3,671 |
10993_4878_R | null | RESTRICTED | 4,878 | 10,993 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute episode of mild to moderate ulcerative proctitis</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute episode of mild to moderate ulcerative proctitis</p> | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
10994_10995_R | Dose modification | AUTHORITY_REQUIRED | 10,995 | 10,994 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)</p><br/><p>Dose modification</p><br/><p>The treatment must be for dose titration purposes.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)</p><br/><p>Dose modification</p><br/><p>The treatment must be for dose titration purposes.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11011_C | null | null | null | null | null | <p>This is a category X drug and must not be given to pregnant women. Pregnancy must be avoided during treatment and for at least 3 months following cessation of therapy.</p> | N | Y | N | null | null | N | 2014-09-01 | 3,671 |
11013_11013_R | Initial treatment | STREAMLINED | 11,013 | 11,013 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic stable atherosclerotic disease</p><br/><p>Initial treatment</p><br/><p>The treatment must be in combination with aspirin, but not with any other anti-platelet therapy; AND</p> <p>Patient must have a diagnosis of coronary artery disease in a... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic stable atherosclerotic disease</p><br/><p>Initial treatment</p><br/><p>The treatment must be in combination with aspirin, but not with any other anti-platelet therapy; AND</p> <p>Patient must have a diagnosis of coronary artery disease in a... | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11014_11057_R | null | STREAMLINED | 11,057 | 11,014 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Asthma</p><br/><p>Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; AND</p> <p>Patient must be aged 18 years or older.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Asthma</p><br/><p>Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; AND</p> <p>Patient must be aged 18 years or older.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11015_11015_R | For combination use with venetoclax treatment cycles 1 to 6 inclusive in first-line therapy | STREAMLINED | 11,015 | 11,015 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)</p><br/><p>For combination use with venetoclax treatment cycles 1 to 6 inclusive in first-line therapy</p><br/><p>The condition must be untreated; AND</p> <p>The treatment must... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)</p><br/><p>For combination use with venetoclax treatment cycles 1 to 6 inclusive in first-line therapy</p><br/><p>The condition must be untreated; AND</p> <p>The treatment must... | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11047_11066_R | Continuing or change of treatment | STREAMLINED | 11,066 | 11,047 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing or change of treatment</p><br/><p>Patient must have previously received PBS-subsidised therapy for HIV infection.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing or change of treatment</p><br/><p>Patient must have previously received PBS-subsidised therapy for HIV infection.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11059_11070_R | null | STREAMLINED | 11,070 | 11,059 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic renal failure</p><br/><p>Patient must be a child aged 3 years or older; AND</p> <p>Patient must require treatment with a low protein and a low phosphorus diet; or</p> <p>Patient must require treatment with a low protein, low phosphorus and ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic renal failure</p><br/><p>Patient must be a child aged 3 years or older; AND</p> <p>Patient must require treatment with a low protein and a low phosphorus diet; or</p> <p>Patient must require treatment with a low protein, low phosphorus and ... | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11065_5520_R | null | STREAMLINED | 5,520 | 11,065 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven Pseudomonas aeruginosa infection</p><br/><p>Patient must have cystic fibrosis; AND</p> <p>The treatment must be for management.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven Pseudomonas aeruginosa infection</p><br/><p>Patient must have cystic fibrosis; AND</p> <p>The treatment must be for management.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11067_11017_R | First continuing treatment (treatment cycles 2 to 6 inclusive) of first-line therapy | AUTHORITY_REQUIRED | 11,017 | 11,067 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)</p><br/><p>First continuing treatment (treatment cycles 2 to 6 inclusive) of first-line therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)</p><br/><p>First continuing treatment (treatment cycles 2 to 6 inclusive) of first-line therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with t... | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11068_11069_R | Continuing treatment | AUTHORITY_REQUIRED | 11,069 | 11,068 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL)</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must be in combination with rituximab for up t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic lymphocytic leukaemia (CLL)</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must be in combination with rituximab for up t... | N | N | N | IMMEDIATE | ALL | N | 2020-12-01 | 3,671 |
11078_11081_R | null | STREAMLINED | 11,081 | 11,078 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Epileptic seizures</p><br/><p>The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs; or</p> <p>Patient must be a woman of childbearing potential.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Epileptic seizures</p><br/><p>The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs; or</p> <p>Patient must be a woman of childbearing potential.</p> <p align="justify"><b>Continuing Therapy Only:</b></p><p al... | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11085_11153_R | Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,153 | 11,085 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11088_11154_R | Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,154 | 11,088 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11092_11120_R | Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3, Whole body or Face, hand, foot (re-commencement of treatment after a break in biologic... | AUTHORITY_REQUIRED | 11,120 | 11,092 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | N | N | Y | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11099_11099_R | null | RESTRICTED | 11,099 | 11,099 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Multiple myeloma</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Multiple myeloma</p> | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11100_11160_R | Initial treatment | STREAMLINED | 11,160 | 11,100 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must have a WHO performance stat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must have a WHO performance stat... | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11101_11077_R | null | STREAMLINED | 11,077 | 11,101 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Partial epileptic seizures</p><br/><p>The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs; or</p> <p>Patient must be a woman of childbearing potential; AND</p> <p>Patient must be unable to take a solid dose ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Partial epileptic seizures</p><br/><p>The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs; or</p> <p>Patient must be a woman of childbearing potential; AND</p> <p>Patient must be unable to take a solid dose ... | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11105_11143_R | null | RESTRICTED | 11,143 | 11,105 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection</p><br/><p>Patient must have at least one of the following prior to having the latest PBS-subsidised prescription issued: (i) a negative HIV test result no older t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection</p><br/><p>Patient must have at least one of the following prior to having the latest PBS-subsidised prescription issued: (i) a negative HIV test result no older t... | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11106_11138_R | Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,138 | 11,106 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11110_8296_R | Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply | AUTHORITY_REQUIRED | 8,296 | 11,110 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug under the first continuing treatment... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug under the first continuing treatment... | N | N | Y | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11118_11145_R | Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,145 | 11,118 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11121_11089_R | Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,089 | 11,121 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised trea... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11132_11116_R | null | STREAMLINED | 11,116 | 11,132 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Partial epileptic seizures</p><br/><p>The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs; or</p> <p>Patient must be a woman of childbearing potential; AND</p> <p>The treatment must not be given concomitantl... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Partial epileptic seizures</p><br/><p>The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs; or</p> <p>Patient must be a woman of childbearing potential; AND</p> <p>The treatment must not be given concomitantl... | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11134_11107_R | Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3, Whole body or Face, hand, foot (re-commencement of treatment after a break in biologic... | AUTHORITY_REQUIRED | 11,107 | 11,134 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | N | N | Y | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11135_11161_R | Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,161 | 11,135 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 3, Whole body (re-commencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Patient must have previously received PBS-subsidised treatment ... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11139_11090_R | Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,090 | 11,139 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11140_11096_R | Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,096 | 11,140 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Whole body (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treat... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11144_11119_R | Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,119 | 11,144 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11163_11123_R | Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,123 | 11,163 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11167_11168_R | Initial treatment | STREAMLINED | 11,168 | 11,167 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must not be suita... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must not be suita... | N | N | N | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11173_11158_R | Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3, Whole body or Face, hand, foot (re-commencement of treatment after a break in biologic... | AUTHORITY_REQUIRED | 11,158 | 11,173 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less... | N | N | Y | IMMEDIATE | ALL | N | 2021-01-01 | 3,671 |
11175_11130_R | Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,130 | 11,175 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Initial treatment - Initial 2, Face, hand, foot (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised... | N | N | Y | FULL | ALL | N | 2021-01-01 | 3,671 |
11192_11195_R | Initial treatment following dose titration | AUTHORITY_REQUIRED | 11,195 | 11,192 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pulmonary arterial hypertension (PAH)</p><br/><p>Initial treatment following dose titration</p><br/><p>Patient must have WHO Functional Class III PAH at treatment initiation with this drug; or</p> <p>Patient must have WHO Functional Class IV PAH at... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pulmonary arterial hypertension (PAH)</p><br/><p>Initial treatment following dose titration</p><br/><p>Patient must have WHO Functional Class III PAH at treatment initiation with this drug; or</p> <p>Patient must have WHO Functional Class IV PAH at... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11193_11193_R | Continuing treatment | AUTHORITY_REQUIRED | 11,193 | 11,193 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pulmonary arterial hypertension (PAH)</p><br/><p>Continuing treatment</p><br/><p>Patient must have received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must not have developed disease progression while receiving t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pulmonary arterial hypertension (PAH)</p><br/><p>Continuing treatment</p><br/><p>Patient must have received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must not have developed disease progression while receiving t... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11207_9183_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 9,183 | 11,207 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p> <p>Patient must have failed to achieve an ad... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p> <p>Patient must have failed to achieve an ad... | N | N | Y | FULL | ALL | N | 2021-02-01 | 3,671 |
11208_9105_R | Continuing treatment | AUTHORITY_REQUIRED | 9,105 | 11,208 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient must have re... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient must have re... | N | N | Y | FULL | ALL | N | 2021-02-01 | 3,671 |
11209_8830_R | Continuing treatment, Whole body | AUTHORITY_REQUIRED | 8,830 | 11,209 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have... | N | N | Y | FULL | ALL | N | 2021-02-01 | 3,671 |
11210_4312_R | Initial treatment for up to 6 months | AUTHORITY_REQUIRED | 4,312 | 11,210 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gast... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gast... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11211_4352_R | Initial treatment for up to 6 months | AUTHORITY_REQUIRED | 4,352 | 11,211 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe cows'' milk protein enteropathy with failure to thrive</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe cows'' milk protein enteropathy with failure to thrive</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, ... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11212_4323_R | Initial treatment for up to 6 months | AUTHORITY_REQUIRED | 4,323 | 11,212 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or in consultation with a spec... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or in consultation with a spec... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11213_4345_R | Continuing treatment | AUTHORITY_REQUIRED | 4,345 | 11,213 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe cows'' milk protein enteropathy with failure to thrive</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or have been ass... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe cows'' milk protein enteropathy with failure to thrive</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or have been ass... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11214_4338_R | Continuing treatment | AUTHORITY_REQUIRED | 4,338 | 11,214 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Combined intolerance to cows'' milk protein, soy protein and protein hydrolysate formulae</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and he... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Combined intolerance to cows'' milk protein, soy protein and protein hydrolysate formulae</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and he... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11215_4339_R | Continuing treatment | AUTHORITY_REQUIRED | 4,339 | 11,215 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist a... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Proven combined immunoglobulin E (IgE) mediated allergy to cows'' milk protein and soy protein</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist a... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11216_4330_R | null | AUTHORITY_REQUIRED | 4,330 | 11,216 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk anaphylaxis</p><br/><p>Must be treated by a specialist allergist or clinical immunologist, or in consultation with a specialist allergist or clinical immunologist; AND</p> <p>Patient must be up to the age of 24 months.</p> <p/><p align=... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk anaphylaxis</p><br/><p>Must be treated by a specialist allergist or clinical immunologist, or in consultation with a specialist allergist or clinical immunologist; AND</p> <p>Patient must be up to the age of 24 months.</p> <p/><p align=... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11217_4337_R | Continuing treatment | AUTHORITY_REQUIRED | 4,337 | 11,217 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or have an appointment to be assessed by one o... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cows'' milk protein enteropathy</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or have an appointment to be assessed by one o... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11218_4305_R | Initial treatment for up to 6 months | AUTHORITY_REQUIRED | 4,305 | 11,218 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Combined intolerance to cows'' milk protein, soy protein and protein hydrolysate formulae</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroent... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Combined intolerance to cows'' milk protein, soy protein and protein hydrolysate formulae</p><br/><p>Initial treatment for up to 6 months</p><br/><p>Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroent... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11219_5945_R | Initial treatment for up to 3 months | AUTHORITY_REQUIRED | 5,945 | 11,219 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Eosinophilic oesophagitis</p><br/><p>Initial treatment for up to 3 months</p><br/><p>Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND</p> <p>Patient must require an amino acid based formula as a co... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Eosinophilic oesophagitis</p><br/><p>Initial treatment for up to 3 months</p><br/><p>Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND</p> <p>Patient must require an amino acid based formula as a co... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11220_9276_R | Initial treatment | AUTHORITY_REQUIRED | 9,276 | 11,220 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Myelodysplastic or myeloproliferative disorder</p><br/><p>Initial treatment</p><br/><p>Patient must have confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement by standard karyotyping; or</p> <p>Patient must hav... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Myelodysplastic or myeloproliferative disorder</p><br/><p>Initial treatment</p><br/><p>Patient must have confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement by standard karyotyping; or</p> <p>Patient must hav... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11221_9240_R | Initial treatment | AUTHORITY_REQUIRED | 9,240 | 11,221 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Dermatofibrosarcoma protuberans</p><br/><p>Initial treatment</p><br/><p>The condition must be unresectable; or</p> <p>The condition must be locally recurrent; or</p> <p>The condition must be metastatic; AND</p> <p>The treatment must not exceed a ma... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Dermatofibrosarcoma protuberans</p><br/><p>Initial treatment</p><br/><p>The condition must be unresectable; or</p> <p>The condition must be locally recurrent; or</p> <p>The condition must be metastatic; AND</p> <p>The treatment must not exceed a ma... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11222_4229_R | null | AUTHORITY_REQUIRED | 4,229 | 11,222 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Superficial basal cell carcinoma</p><br/><p>The condition must be previously untreated; AND</p> <p>The condition must be confirmed by biopsy; AND</p> <p>Patient must have normal immune function; AND</p> <p>The condition must not be suitable for tre... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Superficial basal cell carcinoma</p><br/><p>The condition must be previously untreated; AND</p> <p>The condition must be confirmed by biopsy; AND</p> <p>Patient must have normal immune function; AND</p> <p>The condition must not be suitable for tre... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.